Healthcare

ASLAN Pharmaceuticals Limited(ASLN)

Live Price

Offline

$0.60

-14.27% today

1Y Change

—

Window

No data

Market Cap: $777.12M
Revenue Growth: 0.0%
EPS Growth: +26.9%
Dividend Yield: 0.0%

No coverage

Historical coverage is still loading

We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.

No price data

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

ASLAN Pharmaceuticals Limited (ASLN) is a Healthcare stock with a market cap of $777.12M. The stock last traded around $0.60. Baseline metrics include revenue growth of 0.0%, EPS growth of +26.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +26.9%, free cash flow -20.7% with operating margin -364.5% and ROIC -323.1%. Valuation already assumes a fairly strong business story at price/sales 64.8. Stock Foundry combines ASLN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +7.6% peer median

Operating Margin

Below sector median

-364.5% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report landed above expectations

2024 was reported on Aug 9, 2024 with an EPS surprise of +75.6%.

The setup is mixed rather than one-directional

Revenue is 0.0% and EPS is +26.9%, while operating margin sits near -364.5%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

ASLN

—

Normalized return

SPY

—

S&P 500

Excess Return

—

Relative to SPY

ASLN Max Drawdown

—

Trailing 1Y

SPY Max Drawdown

—

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for ASLN and SPY.

Calendar-year return history is still loading or unavailable.

Company Overview

ASLAN Pharmaceuticals Limited

Last Updated: May 7, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E: —
EV/EBITDA: —
Price/Sales: 64.8
Price/Book: —

Growth

Revenue: 0.0%
EPS: +26.9%
Free Cash Flow: -20.7%

Profitability

Gross Margin: 97.1%
Operating Margin: -364.5%
Net Margin: -368.5%
ROE: 1796.9%
ROIC: -323.1%

Balance Sheet

Debt/Equity: —
Current Ratio: 1.84

Earnings Reports

📅 Last reportedAug 9, 2024

Period	B/M	EPS	EPS Δ	Revenue	Rev Δ
— Aug 9, 24	✓	-0.88 Est -3.60	+75.6%	— Est —	—
— Apr 12, 24	✗	-6.24 Est -0.61	-923.0%	— Est —	—
— Mar 29, 24	✗	-0.78 Est -0.65	-20.0%	— Est —	—
— Oct 27, 23	✓	-4.48 Est -6.80	+34.1%	— Est —	—
— Aug 11, 23	✓	-0.88 Est -6.96	+87.4%	12000.0B Est —	—
— Apr 28, 23	✗	-10.32 Est -6.40	-61.3%	— Est —	—
— Mar 24, 23	✗	-8.32 Est -7.60	-9.5%	— Est —	—
— Oct 28, 22	✓	-6.40 Est -8.00	+20.0%	— Est —	—
— Aug 12, 22	✓	-7.60 Est -8.00	+5.0%	— Est —	—
— Apr 27, 22	✗	-7.60 Est -6.80	-11.8%	— Est —	—
— Mar 25, 22	✗	-6.40 Est -6.00	-6.7%	— Est —	—
— Oct 26, 21	—	-4.80 Est -4.80	0.0%	— Est —	—
— Aug 6, 21	✓	-3.20 Est -4.40	+27.3%	— Est —	—
— Apr 22, 21	✗	-6.00 Est -2.75	-118.2%	— Est —	—
— Mar 18, 21	✓	-0.72 Est -2.75	+73.9%	— Est —	—
— Nov 9, 20	✓	-0.80 Est -4.00	+80.0%	— Est —	—

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official

No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guide Read how to compare stocks